Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer

There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioav...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyar, Stephen, Moreno-Aspitia, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235996/
https://www.ncbi.nlm.nih.gov/pubmed/22174585
http://dx.doi.org/10.4137/BCBCR.S7379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235996/
https://www.ncbi.nlm.nih.gov/pubmed/22174585
http://dx.doi.org/10.4137/BCBCR.S7379

Ejemplares similares